Latest Market Positioning News

Aguia Resources reports a significant uplift in the economics of its Tres Estrades Phosphate Project in Brazil, driven by soaring phosphate prices and a streamlined production strategy targeting early 2026 start-up.

Audeara Ltd has reported a landmark FY25 with record cash receipts of $4.9 million, driven by strong domestic sales and expanding global technology partnerships. The company’s strategic R&D and inventory build set the stage for further growth in FY26.

Regis Healthcare has agreed to acquire four premium aged care homes in South-East Queensland from Rockpool, adding 600 beds and boosting its portfolio to 72 homes. The $135 million deal is expected to be earnings accretive in FY26.

Mount Gibson Iron Limited reports steady FY25 iron ore sales amid operational challenges and announces a strategic entry into gold with a 50% stake in the Central Tanami Project.

Lynas Rare Earths has achieved record quarterly production of key rare earth elements and reported a strong 38% increase in sales revenue, while advancing its Mt Weld expansion and signing strategic MOUs in Malaysia.

Canadian Phosphate Limited advances its Canadian operations with new bulk sampling permits and a promising exploration target, while steady sales and customer upgrades signal growth ahead.

Matsa Resources has officially commenced gold production at its Devon Pit Gold Mine, marking a pivotal step backed by a robust feasibility study and strategic agreements. The company is advancing exploration and progressing a significant transaction with AngloGold Ashanti, positioning itself for growth.

Sayona Mining has updated its timetable for the merger with Piedmont Lithium, conditional placement, and share consolidation, aiming to simplify and speed up the process pending shareholder approval.

Rimfire Pacific Mining has secured $3.5 million through a discounted share placement to accelerate scandium resource development across its NSW projects, signaling renewed momentum after arbitration setbacks.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

Aerometrex has completed a strategic review that delivers $2 million in cost savings and initiates data monetisation, positioning the company for accelerated growth in FY26.

Elsight Limited reports record-breaking revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market opportunities, positioning the company for profitability later this year.